Bedrijfsoverzicht
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company that specializes in developing small molecules designed to treat obesity and other metabolic disorders, specifically targeting the limitations of current injectable therapies. The firm operates within the Healthcare sector, specifically under the Biotechnology industry, which implies a focus on research and development of biological treatments rather than established commercial products. The company's current financial scale is characterized by a market capitalization of $6.45M, annual revenue of $5,000, and an employee count of 1. These figures indicate that the company is in an extremely early stage of development with negligible operational footprint, reflecting a typical profile for a pre-revenue biotechnology entity where value is derived primarily from intellectual property potential rather than current sales volume or workforce size. The minimal revenue generation coupled with a single employee suggests that the business model relies heavily on external funding mechanisms to sustain operations while clinical trials progress toward potential regulatory approval.
Financiële gezondheid
The financial statements for Alaunos Therapeutics, Inc. reveal a revenue of $5,000 over the trailing twelve months, a net income of $-4,282,000, and an EBITDA of $-4,218,000. The substantial disparity between the nominal revenue of $5,000 and the significant net loss of $4.282 million indicates an operational cost structure that is entirely driven by research, development, and administrative expenses rather than cost of goods sold, which is typical for clinical-stage biotechnology firms. The free cash flow stands at $-753,625, which signifies that the company is burning through its cash reserves to fund ongoing operations and cannot yet generate positive cash flow from its business activities. Regarding liquidity and leverage, the company holds $1.39M in cash and has $0 in debt, resulting in a debt-to-equity ratio that is listed as N/A due to the lack of equity or debt denominator values suitable for calculation. Despite the absence of debt, the company maintains a current ratio of 2.44, which indicates a conservative balance sheet with sufficient current assets to cover short-term liabilities, providing a safety buffer despite the cash burn rate. Return on Equity is reported at -198.1% and Return on Assets at -92.3%, metrics that reveal management is currently generating negative returns on the capital employed, a standard characteristic for companies in the R&D phase that have not yet achieved commercial viability. The gross margin, operating margin, and profit margin are all recorded at 0.0% or effectively zero relative to the tiny revenue base, highlighting that the company has not yet reached a scale where fixed costs are amortized over significant sales.
Waarderingsbeoordeling
Valuation metrics for Alaunos Therapeutics, Inc. reflect its status as a loss-making entity, with a trailing P/E ratio of N/A and a forward P/E of -4.82. The distinction between a non-existent trailing P/E and a negative forward P/E implies that analysts and markets are pricing the stock based on future potential earnings rather than historical performance, acknowledging that current earnings are negative and will remain so until commercialization milestones are met. The price-to-book ratio is 2.27, suggesting that the market values the company at a premium of 2.27 times its net asset value, a common occurrence in biotechnology where intangible assets like patents and pipeline value are not fully captured on the balance sheet. Alternative valuation metrics such as a price-to-sales ratio of 1290.00 and an EV/EBITDA of -1.30 further illustrate that traditional valuation multiples are distorted by the lack of revenue and earnings, forcing reliance on pipeline value and cash runway as primary valuation drivers. Price action shows a 52-week high of $6.20 and a 52-week low of $1.67, meaning the stock trades within a wide volatility band where the current price position must be evaluated against the $6.20 ceiling and $1.67 floor to understand the range of investor sentiment. The beta value is recorded as -1.13, which is an anomalous figure for equities that typically indicates an inverse correlation with the broader market, suggesting extreme price volatility where the stock may move in the opposite direction of the market index, potentially due to specific biotech sector dynamics or trading liquidity issues.
Growth & Income
The company's growth profile is defined by a revenue growth year-over-year of -25.0%, while earnings growth is listed as N/A due to the absence of prior comparable earnings data. This negative revenue growth combined with non-existent earnings growth implies that the business is not yet in a commercial scaling phase where revenue expansion can outpace costs, but rather in a phase of contraction or initial market entry where sales figures are minimal and volatile. Alaunos Therapeutics, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company retains all available resources and cash to reinvest into its research pipeline and clinical development rather than distributing income to shareholders. Consequently, the overall growth and income profile is one of capital deployment for long-term asset creation rather than immediate income generation, relying entirely on the successful transition of its clinical-stage oncology and obesity therapies into the market to achieve future profitability.